Short answer: GLP-1, GIP and glucagon are peptide hormones that help coordinate metabolism. They are related signals, but they act through different receptors and do not do the same job.
What people mean by GLP-1 peptides
GLP-1 stands for glucagon-like peptide-1. The body makes this hormone, including in intestinal cells. Its biological effects include helping coordinate insulin secretion with nutrient availability. In everyday conversation, “GLP-1” is also used loosely for medicines that activate the GLP-1 receptor. The natural hormone, a manufactured medicine and an unapproved product sold online are not interchangeable categories.
A receptor is a protein that recognizes a signal and converts that interaction into cellular activity. The GLP-1 receptor crosses the cell membrane and communicates with proteins inside the cell. Structural experiments have visualized how a peptide occupies the receptor and stabilizes an active configuration. The receptor commonly signals through the stimulatory G protein, Gs, with downstream changes in cyclic AMP. This is a molecular explanation, not a prediction of what a particular person will experience. Activated GLP-1 receptor structure
How GIP differs
GIP means glucose-dependent insulinotropic polypeptide. It is another incretin hormone, meaning it participates in the insulin response associated with eating. GIP has its own receptor. A compound can be designed to activate both GIP and GLP-1 receptors, but the strength and pattern of its signaling may differ at each one. Laboratory structural work on tirzepatide illustrates this: “dual agonist” describes two receptor targets, not identical action at both. Structural determinants of tirzepatide signaling
Where glucagon fits
Glucagon is released by pancreatic alpha cells and helps the liver supply glucose when needed. It should not be confused with GLP-1 simply because the names overlap. Glucose control depends on coordinated signals rather than a single hormone acting alone. NIDDK research overview
A useful way to read metabolic research is to ask which receptor was studied, in which tissue, and with which outcome. Binding to a receptor, changing a laboratory signal, lowering a blood marker and improving a clinical outcome are separate findings. None should silently substitute for the others.
You might be wondering
Where this question leads.
Follow the source material.
Links are preserved from the supplied draft manuscripts. Linked sources may change. Regulatory wording needs a fresh specialist check before public launch.
